Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel, Pembrolizumab +/- Bevacizumab in pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer
NCT07198074Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in endometrial cancer (EC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival up to 5 years. Started Jan 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07198074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198074.